CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVODOPA	IMPURITIES	*USP37–NF32*	3533	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Row 6 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
							Supplement to USP38–NF33	Column 1 of *Table 1*: Change 1-Veratrylglycine to: L-Veratrylglycine[a] AND Add a footnote: [a] 3-(3,4-Dimethoxyphenyl)-L-alanine.
VINBLASTINE SULFATE	IDENTIFICATION/*B.*	*USP37–NF32*	5150	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Sample*: Change 100 mg/mL in water to: 10 mg/mL in water
CEFADROXIL	ASSAY/ *Procedure*	*First Supplement to USP37–NF32*	6602	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3 of *Sample solution*: Change USP Cefadroxil RS to: Cefadroxil
METHODS	LIGHT OBSCU	*USP37–NF32*	1301	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 26 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS	RATION PARTICLE COUNT TEST/ *Instrument Standardization Tests*/*Particle Counting Accuracy—System Suitability*						*Supplement to USP38–NF33*	*Method 1—MWHC Instruments*: Change P_B is the average particle count obtained from the suspension; to: P_S is the average particle count obtained from the suspension;
TERBINAFINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP37–NF32*	6704	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Terbinafine Related Compound A RS: Change *N*-Methyl-*C*-(naphthalen-1-yl)methanamine. to: *N*-Methyl-*C*-(naphthalen-1-yl)methanamine hydrochloride.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 2 of USP Terbinafine Related Compound B RS: Change (2*Z*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-1- ylmethyl)hept-2- en-4-yn-1-amin e. to: (2*Z*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-1- ylmethyl)hept-2- en-4-yn-1-amin e hydrochloride. AND Line 2 of USP Terbinafine Related Compound C: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(2*E*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-2- ylmethyl)hept-2- en-4-yn-1-amin e. to: (2*E*)-*N* , 6, 6-Tr imethyl-*N* -(naphthalen-2- ylmethyl)hept-2- en-4-yn-1-amin e hydrochloride. AND Line 2 of Terbinafine Related Compound D RS: Change (2*E*)-*N* , 6, 6-Tr imethyl-*N* -[(4-methylnaph

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								thalen-1-yl)methyl]hept-2-en-4-yn-1-amine. to: (2*E*)-*N* , 6, 6-Trimethyl-*N* -[(4-methylnaphthalen-1-yl)methyl]hept-2-en-4-yn-1-amine hydrochloride.
CEFTIZOXIME FOR INJECTION	*Constituted solution*	*USP37–NF32*	2240	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1: Change At the time of use, it meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: At the time of use, it meets the requirements for *Constituted Solutions* under *Injections <1>*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXAPRAM HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USP37–NF32*	2708	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 7 of *Analysis*: Change R_U = peak response ratio of the doxapram to the internal standard from the *Sample solution* R_S = peak response ratio of the doxapram to the internal standard from the *Sample solution* to: R_U = peak response ratio of doxapram to the internal standard from the *Sample solution* R_S = peak response ratio of doxapram to the internal standard from the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution
LEFLUNOMIDE	IMPURITIES/*Organic Impurities*/*Procedure 2*	*USP37–NF32*	3502	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 3 of *Analysis*: Change [Note—Disregard any peak with an area less than the leflunomide peak from the *System suitability solution*. to: [Note—Disregard any peak with an area less than the leflunomide peak from the *Sensitivity solution*.
NALTREXONE HYDROCHLORIDE	*Assay*	*USP37–NF32*	3922	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 7 of *Procedure*: Change (377.86/341.41) $10C(r_U/r_S)$ in which 377.86 and 341.41 are the molecular weights of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								naltrexone hydrochloride and naltrexone to: (377.86/341.40)10$C(r_U/r_S)$ in which 377.86 and 341.40 are the molecular weights of naltrexone hydrochloride and naltrexone
VITAMIN E ASSAY	ASSAY/ *Procedure 4/ Chromatographic system*	*First Supplement to USP37–NF32*	6338	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Flow rate*: Change 1.5 mL/min to: 1 mL/min
GENERAL NOTICES TO USP-NF	6. TESTING PRACTICES AND PROCEDURES/*6.50. Preparation of Solutions*	*First Supplement to USP37–NF32*	6291	25-Jul-2014	1-Aug-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *6.50.20. Solutions*: Change An expression such as “(1 in 10)” means that 1 part *by volume* of a liquid shall be diluted with a sufficient quantity of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								diluent or solvent to make the volume of the finished solution 10 parts *by volume*. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated. to: An expression such as “(1 in 10)” means that 1 part *by volume* of a liquid shall be diluted with, or 1 part *by weight* of a solid shall be dissolved in, a sufficient

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								quantity of the diluent or solvent to make the volume of the finished solution 10 parts *by volume*. An expression such as “(20:5:2)” means that the respective numbers of parts, by volume, of the designated liquids shall be mixed, unless otherwise indicated.
SUFENTANIL CITRATE	ASSAY/ *Procedure/System suitability/Suitability requirements*	*First Supplement to USP37–NF32*	6701	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Relative standard deviation*: Change NMT 0.7% to: NMT 0.73%
BUMETANIDE	IMPURITIES	*USP37–NF32*	2024	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 4 of Column 1 of *Table 1*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Paroxetine butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate to: Butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate
ROPINIROLE HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 1/System suitability/Suitability requirements*	*Revision Bulletin (Official May 01, 2014)*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Tailing factor*: Change NLT 2.0 for the ropinirole peak to: NMT 2.0 for the ropinirole peak
CHLORDIAZEPOXIDE HYDROCHLORIDE FOR INJECTION	*Constituted solution*	*USP37–NF32*	2290	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1: Change At the time of use, it meets the requirements for *Constituted Solutions* under *Labeling* under *Injections <1>*. to: At the time of use, it meets the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								requirements for *Constituted Solutions* under *Injections <1>*.
ERGOTAMINE TARTRATE	*Identification*	*USP37–NF32*	2826	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 4:Change value as the principal spot of *Standard solution A*. to: values as the corresponding spots of the *Standard preparation*.
LEVOTHYROXINE SODIUM TABLETS	IMPURITIES/*Organic Impurities/Procedure: Limit of Liothyronine Sodium*	*USP37–NF32*	3548	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Acceptance criteria*: Change NMT 2.0% of liothyronine to: NMT 2.0% of liothyronine sodium
VITAMIN E	IDENTIFICATION/*A./Sample solutions*	*USP37–NF32*	5163	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Lines 4 and 7 of *Alpha tocopheryl acetate*: Change dilute sulfuric acid

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: diluted sulfuric acid
CEFADROXIL CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP37–NF32*	6604	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Cefadroxil Related Compound I RS: Change (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(4-hydroxyphenyl) acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate. to: (6*R*,7*R*)-7-[(*R*)-2-Amino-2-(4-hydroxyphenyl) acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid.
ALLOPURINOL	*USP Reference*	*USP37–NF32*	1649	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	standards <11>						*Supplement to USP38–NF33*	Allopurinol Related Compound C RS: Change *N*-(4*H*-1,2,4-Triazol-4-yl)-1*H*-pyrazole-4-carboxamide. to: 5-(4*H*-1,2,4-Triazol-4-yl)-1*H*-pyrazole-4-carboxamide.
RISPERIDONE ORAL SOLUTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Second Supplement to USP37–NF32*	Online	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Risperidone Related Compounds Mixture RS: Change Contains a mixture of the following four compounds: 98.9% of *Risperidone*. 0.5% of *Risperidone cis-N-oxide*: *cis*-3-[2-[4-(6-Fluor

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								o-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-*N*-oxide. 0.3% of *Bicyclorisperidone*: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4-oxo-4*H*-pyrido-[1,2-*a*]pyrimidin-3-yl)ethyl]-1-aza-2-azoniabicyclo[2.2.2]oct-2-ene iodide. 0.3% of *Z-Oxime*: (*Z*)-3-[2-[4-(2,4-Dif

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								luorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one. to: Contains a mixture of the following four compounds: Risperidone. Risperidone *cis*-*N*-oxide: *cis*-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one, *N*-oxide. Bicyclorisperido

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ne: 3-(4-Fluoro-2-hydroxyphenyl)-1-[2-(6,7,8,9-tetrahydro-2-methyl-4 -oxo-4*H* -pyr ido-[1,2 -*a*]pyrimidin-3-yl)ethyl]-2-aza-1-azoniabicyclo[2.2.2]oct-2-ene iodide. *Z*-Oxime: (*Z*)-3-[2-[4-(2,4-Difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4*H* -pyri do[1,2-*a*]pyrimidin-4-one .
CEFTRIAXONE INJECTION	*Assay*	*USP37–NF32*	2241	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *pH 7.0 Buffer*, *pH 5.0 Buffer*, *Mobile phase*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation, *Resolution solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Ceftriaxone Sodium*. to: *pH 7.0 Buffer*—Dissolve 13.6 g of dibasic potassium phosphate and 4.0 g of monobasic potassium phosphate in water to obtain 1000 mL of solution. Adjust this solution with phosphoric acid or 10 N potassium hydroxide to a pH of 7.0 ± 0.1.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								pH 5.0 Buffer—Dissolve 25.8 g of sodium citrate in 500 mL of water, adjust with citric acid solution (1 in 5) to a pH of 5.0 ± 0.1, and dilute with water to a volume of 1000 mL. *Mobile phase*—Dissolve 3.2 g of tetrahe ptylammonium bromide in 400 mL of acetonitrile, add 44 mL of *pH 7.0 Buffer* and 4 mL of *pH 5.0 Buffer*, and add water to make 1000 mL. Pass through a membrane filter of 0.5-?m or finer porosity, and degas.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Standard preparation*—Dissolve an accurately weighed quantity of USP Ceftriaxone Sodium RS in *Mobile phase* to obtain a solution having a known concentration of about 0.2 mg per mL. Use this solution promptly after preparation. *Resolution solution*—Dissolve a suitable quantity of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Ceftriaxone Sodium *E* -Isomer RS in *Standard preparation*, and dilute with *Mobile phase* to obtain a solution containing about 160 µg of USP Ceftriaxone Sodium *E* -Isomer RSper mL and 160 µg of USP Ceftriaxone Sodium RSper mL. Use this solution promptly after preparation. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a 270-nm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								detector and a 4.0-mm × 15-cm column that contains 5-?m packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*. The resolution, *R*, between the ceftriaxone *E* -isomer and ceftriaxone peaks is not less than 3. Chromatograph the *Standard preparation*, and record the peak responses as directed under *Procedure*. The column

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								efficiency determined from the analyte peak is not less than 1500 theoretical plates, the tailing factor for the analyte is not more than 2, and the relative standard deviation for replicate injections is not more than 2%. AND Change *Proce dure*—Proceed as directed for *Procedure* in the *Assay* under *Ceftriaxone Sodium*. Calculate the quantity, in mg, of ceftriaxone ($C_{18}H_{18}N_8O_7S_3$) in each mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the Injection taken by the formula: $200(C / V)(r_U / r_S)$ in which V is the volume, in mL, of Injection taken; and the other terms are as defined therein. to: *Procedure*—Separately inject equal volumes (about 20 ?L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXEPIN HYD	PERFORMANC	*USP37–NF32*	2712	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Calculate the quantity, in mg, of ceftriaxone ($C_{18}H_{18}N_8O_7S_3$) in each mL of Injection taken by the formula: $200(C / V)(r_U / r_S)$ in which C is the concentration, in mg per mL, of USP Ceftriaxone Sodium RS in the *Standard preparation*; V is the volume, in mL, of Injection taken; and r_U and r_S are the ceftriaxone peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively. Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ROCHLORIDE CAPSULES	E TESTS						*Supplement to USP38–NF33*	*Uniformity of Dosage Units, Content Uniformity <905>* to: *Uniformity of Dosage Units <905>*: Meet the requirements The following procedure is used where the test for *Content Uniformity* is required. *Procedure for Content Uniformity* AND Delete a subsection: *Acceptance criteria:* Meet the requirements
LEVALBUTEROL HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference*	*USP37–NF32*	3513	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 2 of USP Levalbuterol Related Compound H

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol. $C_{14}H_{23}NO_3$ 253.34 to: 4-[2-(*tert*-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol acetate. $C_{14}H_{23}NO_3 \cdot C_2H_4O_2$ 313.39
TICLOPIDINE HYDROCHLORIDE	IMPURITIES	*USP37–NF32*	4958	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *Residue on Ignition <231>* to: *Residue on Ignition <281>*
ATROPINE SULFATE	ASSAY/*Procedure*/*System suitability*/*Suitability requirements*	*First Supplement to USP37–NF32*	6591	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1of *Relative standard deviation*: Change NMT 1.0 to: NMT 1.0%
PHARMACEU	DEFINITIONS	*USP37–NF32*	403	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TICAL COMPOUNDING—NONSTERILE PREPARATIONS							*Supplement to USP38–NF33*	*Beyond-Use Date (BUD)*: Change The date after which a compounded preparation should not to be used; to: The date after which a compounded preparation shall not be used;
TERBINAFINE HYDROCHLORIDE	IMPURITIES	*First Supplement to USP37–NF32*	6704	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Footnotes b, c, and d of *Table 2*: Change [b]*trans*-Isoterbinafine or (*E*)-*N*,6,6-trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine. [c]*cis*-Terbinafine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								or (*Z*)-*N*,6,6-trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine.[d] 4-Methylterbinafine or (*E*)-*N*,6,6-trimethyl-*N*-((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine. to:[b] *trans*-Isoterbinafine or (2*E*)-*N*,6,6-Trimethyl-*N*-(naphthalen-2-ylmethyl)hept-2-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								en-4-yn-1-amine. [c] *cis*-Terbinafine or (2*Z*)-*N*, 6, 6-Trimethyl-*N*-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine. [d] 4-Methylterbinafine or (2*E*)-*N*, 6, 6-Trimethyl-*N*-((4-methylnaphthalen-1-yl)methyl)hept-2-en-4-yn-1-amine.
CEFAZOLIN INJECTION	*Assay*	*USP37–NF32*	2190	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Change *pH 3.6 Buffer*, *pH 7.0 Buffer*, *Mobile phase*, *Internal standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Cefazolin*. to: *pH 3.6 Buffer*—Dissolve 0.900 g of anhydrous dibasic sodium phosphate and 1.298 g of citric acid monohydrate in water to make 1000 mL. *pH 7.0 Buffer*—Dissolve 5.68 g of anhydrous dibasic sodium phosphate and 3.63 g of monobasic potassium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phosphate in water to make 1000 mL. *Mobile phase*—Prepare a suitable mixture of *pH 3.6 Buffer* and acetonitrile (9:1). Pass through a membrane filter having a 10-?m or finer porosity, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *Internal standard solution*—Transfer 750 mg of salicylic acid to a 100-mL volumetric flask, dissolve in 10

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL of methanol, dilute with *pH 7.0 Buffer* to volume, and mix. *Standard preparation*—Transfer about 25 mg of USP Cefazolin RS, accurately weighed, to a 25-mL volumetric flask, dissolve in and dilute with *pH 7.0 Buffer* to volume, and mix. Transfer 5.0 mL of this solution to a 100-mL volumetric flask, add 5.0 mL of *Internal standard solution*, dilute with *pH 7.0 Buffer* to volume, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mix. *Chromatographic system* (see *Chromatography <621>*)—The liquid chromatograph is equipped with a 254-nm detector and a 4.0-mm × 30-cm column that contains 10-?m packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*. The relative retention times are about 0.7 for salicylic acid and 1.0 for cefazolin; the resolution, *R*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								between the analyte and internal standard peaks is not less than 4.0; the column efficiency is not less than 1500 theoretical plates; the tailing factor is not more than 1.5; and the relative standard deviation for replicate injections is not more than 2.0%. AND Change *Procedure*—Proceed as directed for *Procedure* in the *Assay* under *Cefazolin*. Calculate the quantity, in mg, of cefazolin

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								($C_{14}H_{14}N_8O_4S_3$) in each mL of the Injection taken by the formula: (1000*C* / *V*)(R_U / R_S) in which *V* is the volume, in mL, of Injection taken, and the other terms are as defined therein. to: *Proce dure* —Separately inject equal volumes (about 10 ?L) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								for the major peaks. Calculate the quantity, in mg, of cefazolin ($C_{14}H_{14}N_8O_4S_3$) in each mL of Injection taken by the formula: $(1000C / V)(R_U / R_S)$ in which C is the concentration, in mg per mL, of USP Cefazolin RS, calculated on the anhydrous basis, in the *Standard preparation*; V is the volume, in mL, of Injection taken; and R_U and R_S are the peak response ratios of cefazolin to the internal standard

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								obtained from the *Assay preparation* and the *Standard preparation*, respectively.
CLOPIDOGREL BISULFATE	ASSAY/ *Procedure*	*USP37–NF32*	2422	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *System suitability solution*: Change 25 µg/mL of USP Clopidogrel Bisulfate RS and 50 µg/mL of USP Clopidogrel Related Compound B RS to: 2.5 µg/mL of USP Clopidogrel Bisulfate RS and 5.0 µg/mL of USP Clopidogrel Related Compound B

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLAVOXATE HYDROCHLORIDE	IMPURITIES RS	*USP37–NF32*	2988	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Row 3 of Column 1 of *Impurity Table 1*: Change Flavoxate related compound A[a,*] to: Flavoxate related compound A[a] AND Row 4 of Column 1 of *Impurity Table 1*: Change Flavoxate related compound B[b,*] to: Flavoxate related compound B[b] AND Row 5 of Column 1 of *Impurity Table 1*: Change Flavoxate related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								compound C[c,]* to: Flavoxate related compound C[c] AND Delete footnote *
MITOTANE TABLETS	*Assay*	*USP37–NF32*	3858	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Procedure*: Change Proceed as directed in the *Assay* under *Mitotane*, beginning with “Concomitantly determine the absorbances of both solutions.” to: Concomitantly determine the absorbances of the *Assay preparation* and the *Standard preparation* in 1-cm cells at the wavelength

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of maximum absorbance at about 268 nm, with a suitable s pectrophotomet er, using methanol as the blank. Calculate the quantity, in mg, of $C_{14}H_{10}Cl_4$ in the portion of Tablets taken by the formula: $0.5C(A_U/A_S)$ in which C is the concentration, in mg/mL, of USP Mitotane RS in the *Standard preparation*, and A_U and A_S are the absorbances of the *Assay preparation* and the *Standard preparation*, respectively.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GELATIN	SPECIFIC TESTS/*Sulfur Dioxide/ Analysis*	*USP37–NF32*	5995	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 5 of the variable definition list: Change *m* = actual molarity of the *Titrant* (mol/mL) to: *m* = actual molarity of the *Titrant* (mol/L)
INSULIN ASPART	IDENTIFICATION/*B. Physicochemical Analytical Procedures for Insulins, Peptide Mapping <121.1>/Chromatographic system*	*First Supplement to USP37–NF32*	6647	25-Jul-2014	1-Aug-2014	*USP39–NF34*	*First Supplement to USP38–NF33*	Line 1 of *Column*: Change 4.0-mm × 25-cm; 5-µm packing L7 to: 4.6-mm × 10-cm; 3-?m packing L1
AMIODARONE HYDROCHLORIDE	IMPURITIES/*Organic Impurities/Procedure 1*	*USP37–NF32*	1750	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Acceptance criteria*: Change *Standard solution B* is not more intense to: the *Sample solution* is not more intense

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
QUINIDINE GLUCONATE EXTENDED-RELEASE TABLETS	ASSAY/ *Procedure*	*USP37–NF32*	4515	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *System suitability solution*: Change dihydroquinidine chloride to: dihydroquinidine hydrochloride
DAPSONE TABLETS	IDENTIFICATION/*B. Ultraviolet Absorption <197U>*	*USP37–NF32*	2514	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Delete Nominally 0.01 ?g/mL prepared as follows.
SULFACETAMIDE SODIUM OPHTHALMIC OINTMENT	ASSAY/ *Procedure*	*USP37–NF32*	4765	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Change USP Sulfacetamide Sodium RS to: sulfacetamide sodium
GADOPENTETATE DIMEGLUMINE INJECTION	IDENTIFICATION/*B.*	*USP37–NF32*	3113	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change 364.8 nm to: 368.4 nm

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VALSARTAN	IMPURITIES	*USP37–NF32*	5115	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Footnote a of *Table 1*: Change (*S*)-*N*-Butyryl-*N*-([2?-(1*H*-tetrazole-5-yl)biphen-4-yl]methyl)-valine. to: *N*-Butyryl-*N*-{[2?-(1*H*-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine. AND Footnote b of *Table 1*: Change (*S*)-*N*-Valeryl-*N*-([2?-(1*H*-tetrazole-5-yl)biphen-4-yl]methyl)-valine benzyl ester. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N -Valeryl -*N* -{[2?-(1*H* -tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester.
STRONG IODINE SOLUTION	ASSAY	*USP37–NF32*	3354	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Acceptance criteria* in *Iodine*: Change of iodine (I) to: of iodine (I) in each 100 mL AND Line 1 of *Acceptance criteria* in *Potassium Iodide*: Change potassium iodide (KI) to: potassium iodide (KI) in each 100 mL
ECHINACEA PALLIDA	ADDITIONAL REQUIREMENTS/*USP*	*USP37–NF32*	5353	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5: Change USP Powdered *Echinacea*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Reference Standards <11>							*purpurea* Extract RS to: USP Powdered *Echinacea pallida* Extract RS
MICONAZOLE INJECTION	IDENTIFICATION/*A./ Chromatographic system*	*USP37–NF32*	3831	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Spray reagent*: Change (Dragendorff's reagent) to: (Dragendorff's TS)
POWDERED DECAFFEINATED GREEN TEA EXTRACT	SPECIFIC TESTS	*USP37–NF32*	5438	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 5 of *Analysis* in *Limit of Gallic Acid*: Change Separately calculate the percentages of gallic acid to: Calculate the percentage of gallic acid AND Line 5 of *Analysis* in *Limit of Caffeine*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Separately calculate the percentages of caffeine to: Calculate the percentage of caffeine
DESCRIPTION AND SOLUBILITY	*Racemethionine*	*USP37–NF32*	1523	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6: Change flavors and frangrance. to: flavors and fragrance.
OXCARBAZEPINE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP37–NF32*	4119	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4 of *Standard solution*: Change µg/mL, where *L* is the label claim in mg/Tablet. to: mg/mL, where *L* is the label claim in mg/Tablet.
ATROPINE SULFATE	IMPURITIES	*First Supplement to USP37–NF32*	6591	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Row 6 of Column 1 of *Table 2*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change Hyoscyamine related compound A[e] to: Hyoscyamine related compound A AND Delete footnote e AND Reletter the following footnotes in both the table and footnote definitions: f to e g to f
ALUMINUM CHLOROHYDRATE SOLUTION	ASSAY/ *Procedure 4*	*USP37–NF32*	1686	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Analysis*: Change anhydrous aluminum dichlorohydrate to: anhydrous aluminum chlorohydrate
PYRAZINAMID	*Identification/B:*	*USP37–NF32*	4493	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
E	*Ultraviolet Absorption <197U>*							on the dried basis to: on the anhydrous basis
CHLOROXYLENOL	IMPURITIES/*Organic Impurities*	*USP37–NF32*	2308	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 12 of *Analysis*: Change C_S = concentration of 3,5-dimethylphenol or chloroxylenol related compound A in the *Standard solution* (mg/mL) to: C_S = concentration of 3,5-dimethylphenol or USP Chloroxylenol Related Compound A RS in the *Standard solution* (mg/mL)

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 28
- Page 29
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- …
- Next page Next ›
- Last page Last »